Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20
How Much Larger Is The Next-Generation In Vitro Diagnostics (IVD) Market Expected To Become By 2029 Compared With Its 2025 Level?
The next-generation in vitro diagnostics (IVD) market has experienced rapid expansion in recent years. Its size is projected to increase from $106.97 billion in 2024 to $117.97 billion in 2025, achieving a compound annual growth rate (CAGR) of 10.3%. This historical development can be attributed to several factors, including an increasing geriatric population, augmented government funding, growing investments in genomic research, an uptick in clinical trials, and a rise in consumer health awareness.
The next-generation in vitro diagnostics (IVD) market size is projected to experience substantial growth in the coming years. It is expected to expand to $172.02 billion by 2029, achieving a compound annual growth rate (CAGR) of 9.9%. This projected growth during the forecast period can be attributed to the increasing development of personalized medicine, rising healthcare expenditure, an escalation in research and development activities, the growing prevalence of infectious diseases, and an increase in chronic disease cases. Major developments anticipated in the forecast period include technological innovation, the integration of artificial intelligence and machine learning into diagnostics, advanced diagnostic technologies, personalized medicine approaches, and the evolution of novel biomarkers.
Unlock Your Free Sample Report for Exclusive Market Data:
https://www.thebusinessresearchcompany.com/sample.aspx?id=25848&type=smp
Which Drivers Are Impacting The Next-Generation In Vitro Diagnostics (IVD) Market?
The rising need for personalized medicine is projected to stimulate the expansion of the next-generation in vitro diagnostics (IVD) market in the coming years. Precision medicine represents a medical strategy that tailors disease prevention and care based on an individual’s genetic profile, environment, and lifestyle. This rise in personalized medicine stems from the increasing availability of genomic data, empowering healthcare providers to devise targeted treatments according to a person’s unique genetic makeup, which results in more effective care. Next-generation in vitro diagnostics (IVD) contributes to personalized medicine by offering precise molecular and genetic insights that facilitate tailored treatment and prevention strategies for individual patients. As an example, in February 2024, the Personalized Medicine Coalition, a US-based hospital and health care organization, reported that in 2023, the FDA granted approval to 16 new personalized treatments for rare disease patients, an increase from six in 2022. Consequently, the escalating demand for personalized medicine is fueling the growth of the next-generation in vitro diagnostics (IVD) market.
What Are The Emerging Segments Gaining Attention In The Next-Generation In Vitro Diagnostics (IVD) Market?
The next-generation in vitro diagnostics (ivd) market covered in this report is segmented –
1) By Product Type: Consumables, Instruments, Software
2) By Type: Core Laboratory Diagnostics, Point-Of-Care Testing, Molecular Diagnostics
3) By Application: Oncology Or Cancer, Infectious Diseases, Diabetes, Cardiology , Other Applications
4) By End-User: Hospitals And Clinics, Diagnostic Laboratories, Academic And Research Institutions, Other End Users
Subsegments:
1) By Software: Laboratory Information Management Systems, Specimen Tracking Software Modules, Cloud-Based Tracking Software, Barcode and Radio Frequency Identification Integration Platforms, Mobile Applications for Specimen Tracking
2) By Consumables: Barcode Labels, Radio Frequency Identification Tags, Specimen Bags and Tubes, Labeling Ribbons, Seals and Caps
3) By Hardware: Barcode Scanners, Radio Frequency Identification Readers, Label Printers, Workstations and Terminals, Storage and Transport Monitoring Devices
What Are The Latest Industry Trends Transforming The Next-Generation In Vitro Diagnostics (IVD) Market?
Major companies engaged in the next-generation in vitro diagnostics (IVD) market are adopting a strategic partnerships approach. This method in next-generation IVD involves collaborating with technology providers, research institutions, and healthcare organizations to accelerate innovation, enhance diagnostic accuracy, and expand access to advanced testing solutions for individuals, businesses, and governments. Strategic partnerships refer to a process where companies leverage each other’s strengths and resources to achieve mutual benefits and success. For instance, in October 2024, Yourgene Health, a UK-based biotechnology company, partnered with Genetix, a Colombia-based human genetic diagnosis company, to launch Colombia’s first local non-invasive prenatal testing (NIPT) service. This initiative represents a significant advancement in prenatal care in the region, offering expectant parents faster, more reliable, and cost-effective access to advanced genetic screening. The service utilizes Yourgene Health’s IONA Nx NIPT Workflow, a comprehensive, CE-marked in vitro diagnostic (IVD) solution. This workflow is highly flexible and scalable, suitable for varying sample volumes, and enables Genetix to offer a quality-assured prenatal screening service within Colombia.
Who Are The Core Companies Influencing The Next-Generation In Vitro Diagnostics (IVD) Market Landscape?
Major companies operating in the next-generation in vitro diagnostics (ivd) market are F Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., Abbott Laboratories, Becton Dickinson and Company, Quest Diagnostics Incorporated, Grifols SA, Agilent Technologies Inc., Illumina Inc., Sysmex Corporation, Bio-Rad Laboratories Inc., Revvity Inc., Exact Sciences Corporation, QIAGEN NV, DiaSorin SpA, Singular Genomics Systems Inc., Guardant Health Inc., Pacific Biosciences of California Inc., Transasia Bio-Medicals Ltd., Athena Dx, J Mitra and Co Pvt Ltd
Download The Full Report For Exclusive Market Findings:
Which Region Currently Holds The Largest Share Of The Next-Generation In Vitro Diagnostics (IVD) Market?
North America was the largest region in the next-generation in vitro diagnostics (IVD) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the next-generation in vitro diagnostics (ivd) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Version Of The Next-Generation In Vitro Diagnostics (IVD) Market Report:
https://www.thebusinessresearchcompany.com/customise?id=25848&type=smp
Browse Through More Reports Similar to the Global Next-Generation In Vitro Diagnostics (IVD) Market 2025, By The Business Research Company
In Vitro Diagnostics Ivd Quality Control Global Market Report 2025
In Vitro Diagnostics Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/in-vitro-diagnostics-global-market-report
In Vitro Diagnostic Ivd In Cardiology And Neurology Global Market Report 2025
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model